Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTL-CEBPA in advanced liver cancer
NCT02716012Phase 1Active, not recruiting
- Sponsor
- Mina Alpha Limited
- Start
- Mar 2016
- Primary completion
- Jul 2025
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 3
01
Overview
Phase 1, open-label trial of MTL-CEBPA in hepatocellular carcinoma (HCC), sponsored by Mina Alpha Limited. Started Mar 2016; status: active, not recruiting.
02
Drugs
MTL-CEBPA
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02716012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02716012.